Anxiety disorders can significantly impact daily life, affecting sleep, focus, and overall well-being. In this open-label pilot study, researchers evaluated a hemp-derived, full-spectrum cannabidiol (CBD) product in adults experiencing moderate to severe anxiety symptoms. Participants took the CBD formulation daily over a six-week period while researchers tracked changes in anxiety levels, mood, sleep quality, and cognitive function using standardized clinical assessments. (pubmed.ncbi.nlm.nih.gov)

The study found that participants experienced meaningful reductions in anxiety symptoms along with improvements in sleep and overall quality of life. Cognitive testing showed stable or improved performance in areas such as attention, memory, and executive functioning, indicating that CBD did not negatively affect mental clarity during treatment. The product was generally well tolerated, with few side effects reported, supporting its safety profile within the study’s timeframe. These findings suggest that full-spectrum CBD products may support emotional balance and daily functioning in individuals dealing with anxiety. (pubmed.ncbi.nlm.nih.gov)

Because the trial did not include a placebo control and involved a relatively small group of participants, the authors note that larger randomized clinical studies are needed to confirm effectiveness and determine optimal dosing strategies. Still, the results contribute to growing clinical evidence supporting CBD as a potential supportive option for anxiety management and cognitive wellness. (pubmed.ncbi.nlm.nih.gov)

Source

Smith RT, Dahlgren MK, Sagar KA, et al. Clinical and Cognitive Improvement Following Treatment with a Hemp-Derived, Full-Spectrum, High-Cannabidiol Product in Patients with Anxiety: An Open-Label Pilot Study. Biomedicines. 2025;13(8):1874. PMID: 40868129. National Library of Medicine (NIH): https://pubmed.ncbi.nlm.nih.gov/40868129/